Nyrada Pty Ltd. has synthesized new short transient receptor potential channel 6 (TRPC6) and 7 (TRPC7) antagonists potentially useful for the treatment of cancer.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase CBL-B (CBLB)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety. They are described as potentially useful for the treatment of cancer.
Avelos Therapeutics Inc. has divulged new sulfur or selenium-containing compounds acting as DNA polymerase θ (POLθ; POLQ) inhibitors potentially useful for the treatment of cancer.
A Purdue Research Foundation patent details the discovery of 5/5-5/6 bisaryl compounds acting as mitogen-activated protein kinase kinase kinase 7 (MAP3K7; TAK1) inhibitors reported to be useful for the treatment of multiple myeloma and inflammatory disorders.
Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have identified new macrocyclic GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal and viral infections.
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and HCN2 blockers potentially useful for the treatment of pain, tinnitus, neurological and mood disorders.
Ewha Womans University and Gachon University have discovered new pyrazinocarbazole derivatives acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of colorectal cancer.
RSS